Company profile: Gateway Genomics
1.1 - Company Overview
Company description
- Provider of genetically based tests for families and cancer care, including SneakPeek Early Gender Test to determine fetal sex from a small maternal blood sample as early as six weeks; Foresight Carrier Screen for inherited conditions; Prequel Prenatal Screen to identify risk of chromosomal conditions like Down syndrome from week 10; and oncology tests Prolaris and Precise to assess prostate cancer aggressiveness and tumor variants to guide treatment decisions.
Products and services
- Foresight Carrier Screen: A genetic screening test that determines whether parents carry inherited health conditions that could be passed to a child, enabling carrier status assessment for family planning
- Prequel Prenatal Screen: A prenatal screening test that identifies whether a baby may have increased risk for chromosomal conditions like Down syndrome as early as week 10 of pregnancy
- SneakPeek Early Gender Test: A non-invasive test that determines fetal sex as early as six weeks using a small sample of the mother's blood, enabling early gender insight during pregnancy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Gateway Genomics
DNA Diagnostics Center
HQ: United States
Website
- Description: Provider of paternity and other DNA testing services, including prenatal paternity, ancestry, forensic (for legal and criminal investigations), siblingship, and grandparentage testing. Founded in 1995 and based in Fairfield, Ohio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNA Diagnostics Center company profile →
OncoDNA
HQ: Belgium
Website
- Description: Provider of precision medicine for cancer treatment, leveraging over 60 years’ expertise in medical diagnostics and extensive experience in DNA sequencing and diagnostic analyses in oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoDNA company profile →
Scipher Medicine
HQ: United States
Website
- Description: Provider of a healthcare platform to determine which drug will work best for each patient, offering PrismRA, a blood test that predicts non-response to TNF inhibitors in rheumatoid arthritis; Spectra, a platform that discovers novel drug targets by analyzing patient molecular data and the human interactome; and PrismUC, a diagnostic test for ulcerative colitis utilizing molecular data to guide treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scipher Medicine company profile →
Sividon Diagnostics
HQ: Germany
Website
- Description: Provider of advanced diagnostics that facilitate therapeutic discovery, focused on improving the quality of companion diagnostics in oncology to support future cancer treatment decisions; based in Cologne, Germany, and formed via a management buyout from Siemens Healthcare Diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sividon Diagnostics company profile →
Advanced Cell Diagnostics
HQ: United States
Website
- Description: Provider of molecular pathology cell- and tissue-based diagnostic tests for personalized medicine, including RNAscope for single-molecule, high-specificity RNA detection in intact cells; BaseScope for detecting exon junctions and splice variants in FFPE tissue with morphological context; and miRNAscope for cell-type specific detection of miRNAs, siRNAs, and other small RNAs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Cell Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Gateway Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Gateway Genomics
2.2 - Growth funds investing in similar companies to Gateway Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Gateway Genomics
4.2 - Public trading comparable groups for Gateway Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →